Patents by Inventor Alfred Janetzko
Alfred Janetzko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9915648Abstract: The invention relates to a method of analysing a sample, comprising the analysis of clinical-chemical parameters and the analysis of immunodiagnostic parameters in a fully automatic analysis apparatus, wherein the analysis apparatus comprises a pipetting apparatus, at least one holder for a reagent cartridge containing the components necessary for carrying out the analysis, a holding apparatus for a measurement cell, at least one measurement cell, with each reagent cartridge being associated with a measurement cell, a holding apparatus for a sample container containing sample, and a photometric or spectrometric measurement device. On the basis of a sample it is possible here for a plurality of different clinical-chemical and/or immunodiagnostic parameters to be determined, to which end a dedicated reagent cartridge is inserted into a holding apparatus of the analysis apparatus for each clinical-chemical or immunodiagnostic parameter to be determined.Type: GrantFiled: August 5, 2011Date of Patent: March 13, 2018Assignee: DRG INSTRUMENTS GMBHInventors: Alfred Janetzko, Wilhelm Sänger, Cyril E. Geacintov
-
Patent number: 9778255Abstract: An assembly for selectively performing a clinical chemical test or an ELISA assay including a reagent cartridge with a housing 11 having at least one cavity 12, 13, 14 that contains a reaction or diluting component and having a recess 15 in which a solid phase 20 to which an antigen or antibody can be coupled is inserted into the recess 15 of the housing 11. The assembly also includes at least one measuring cell, wherein a measuring cell is assigned to each reagent cartridge and wherein the reagent cartridge and the measuring cell assigned to it are in a linear assembly in an analytical device.Type: GrantFiled: August 7, 2014Date of Patent: October 3, 2017Assignee: DRG Instruments GMBHInventors: Alfred Janetzko, Wilhelm Sänger, Cyril E. Geacintov
-
Publication number: 20140377785Abstract: An assembly for selectively performing a clinical chemical test or an ELISA assay including a reagent cartridge with a housing 11 having at least one cavity 12, 13, 14 that contains a reaction or diluting component and having a recess 15 in which a solid phase 20 to which an antigen or antibody can be coupled is inserted into the recess 15 of the housing 11. The assembly also includes at least one measuring cell, wherein a measuring cell is assigned to each reagent cartridge and wherein the reagent cartridge and the measuring cell assigned to it are in a linear assembly in an analytical device.Type: ApplicationFiled: August 7, 2014Publication date: December 25, 2014Applicant: DRG INSTRUMENTS GMBHInventors: Alfred Janetzko, Wilhelm Sänger, Cyril E. Geacintov
-
Publication number: 20130183694Abstract: The invention relates to a method of analysing a sample, comprising the analysis of clinical-chemical parameters and the analysis of immunodiagnostic parameters in a fully automatic analysis apparatus, wherein the analysis apparatus comprises a pipetting apparatus, at least one holder for a reagent cartridge containing the components necessary for carrying out the analysis, a holding apparatus for a measurement cell, at least one measurement cell, with each reagent cartridge being associated with a measurement cell, a holding apparatus for a sample container containing sample, and a photometric or spectrometric measurement device. On the basis of a sample it is possible here for a plurality of different clinical-chemical and/or immunodiagnostic parameters to be determined, to which end a dedicated reagent cartridge is inserted into a holding apparatus of the analysis apparatus for each clinical-chemical or immunodiagnostic parameter to be determined.Type: ApplicationFiled: August 5, 2011Publication date: July 18, 2013Applicant: DRG INSTRUMENTS GMBHInventors: Alfred Janetzko, Wilhelm Sänger, Cyril E. Geacintov
-
Patent number: 8304197Abstract: The present invention concerns methods for detecting a hepcidin precursor in a sample from a patient and involves contacting the sample with an antibody or fragment thereof that specifically binds to one or more epitopes of a hepcidin precursor amino acid sequence located within amino acids 20-50 of SEQ ID NO: 2.Type: GrantFiled: July 18, 2011Date of Patent: November 6, 2012Assignee: DRG International, Inc.Inventors: Hasan Kulaksiz, Cyril E. Geacintov, Alfred Janetzko, Wolfgang Stremmel
-
Patent number: 8304258Abstract: The present invention concerns antibodies specific for the C-terminus of human hepcidin, and related methods and kits for diagnosing and/or treating a disease condition characterized by non-physiological levels of hepcidin protein, including prohepcidin and fragments thereof, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the amino acid sequence between and including amino acids 60 and 84, or, in another embodiment, amino acids 74 and 81, as aligned with the human pre-pro-hepcidin precursor protein, and quantifying the pro-hepcidin and/or mature hepcidin level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of prohepcidin/mature hepcidin is indicative of the disease condition.Type: GrantFiled: August 23, 2011Date of Patent: November 6, 2012Assignee: DRG International, Inc.Inventors: Hasan Kulaksiz, Cyril E. Geacintov, Alfred Janetzko
-
Publication number: 20120252109Abstract: The invention relates to a reagent cartridge 10 for an assembly for selectively performing a clinical chemical test or an ELISA assay comprising a housing 11 having at least one cavity 12, 13, 14 that contains a reaction or diluting component and having a recess 15 in which a solid phase 20 to which an antigen or antibody can be coupled is inserted into the recess 15 of the housing 11. It is particularly advantageous if the reagent cartridge 10 comprises three cavities 12, 13, 14 and the reagent cartridge 10 can be used for analyzing clinical chemical parameters, for analyzing immunodiagnostic parameters, for providing additional reagents, and as a diluting cartridge.Type: ApplicationFiled: September 17, 2010Publication date: October 4, 2012Applicant: DRG Instruments GmbHInventors: Alfred Janetzko, Wilhelm Sänger, Cyril E. Geacintov
-
Publication number: 20120003696Abstract: The present invention concerns antibodies specific for the C-terminus of human hepcidin, and related methods and kits for diagnosing and/or treating a disease condition characterized by non-physiological levels of hepcidin protein, including prohepcidin and fragments thereof, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the amino acid sequence between and including amino acids 60 and 84, or, in another embodiment, amino acids 74 and 81, as aligned with the human pre-pro-hepcidin precursor protein, and quantifying the pro-hepcidin and/or mature hepcidin level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of prohepcidin/mature hepcidin is indicative of the disease condition.Type: ApplicationFiled: August 23, 2011Publication date: January 5, 2012Applicant: DRG INTERNATIONAL, INC.Inventors: Hasan Kulaksiz, Cyril E. Geacintov, Alfred Janetzko
-
Publication number: 20110287448Abstract: The present invention concerns methods and kits for diagnosing a disease condition characterized by non-physiological levels of hepcidin, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the mid-portion or C terminus of a hepcidin protein, and quantifying the hepcidin level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of hepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or downregulating hepcidin. The present invention further concerns therapeutic treatment of certain diseases by treatment of subjects with hepcidin and agonists or antagonists of hepcidin.Type: ApplicationFiled: July 8, 2011Publication date: November 24, 2011Applicant: DRG INTERNATIONAL, INC.Inventors: Hasan Kulaksiz, Cyril E. Geacintov, Alfred Janetzko, Wolfgang Stremmel
-
Publication number: 20110275099Abstract: The present invention concerns methods and kits for diagnosing a disease condition characterized by non-physiological levels of hepcidin protein, including prohepcidin and fragments thereof, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the amino acid sequence between and including amino acids 25 and 49 of a hepcidin precursor protein, and quantifying the hepcidin precursor level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of prohepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or downregulating hepcidin.Type: ApplicationFiled: July 18, 2011Publication date: November 10, 2011Applicant: DRG INTERNATIONAL, INC.Inventors: Hasan Kulaksiz, Cyril E. Geacintov, Alfred Janetzko, Wolfgang Stremmel
-
Patent number: 8003338Abstract: The present invention concerns methods and kits for diagnosing a disease condition characterized by non-physiological levels of hepcidin protein, including prohepcidin and fragments thereof, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the amino acid sequence between and including amino acids 25 and 49 of a hepcidin precursor protein, and quantifying the hepcidin precursor level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of prohepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or downregulating hepcidin.Type: GrantFiled: December 2, 2009Date of Patent: August 23, 2011Assignee: DRG International, Inc.Inventors: Hasan Kulaksiz, Cyril E Geacintov, Alfred Janetzko, Wolfgang Stremmel
-
Patent number: 7998691Abstract: The present invention concerns methods and kits for diagnosing a disease condition characterized by non-physiological levels of hepcidin, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the mid-portion or C terminus of a hepcidin protein, and quantifying the hepcidin level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of hepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or downregulating hepcidin. The present invention further concerns therapeutic treatment of certain diseases by treatment of subjects with hepcidin and agonists or antagonists of hepcidin.Type: GrantFiled: May 24, 2010Date of Patent: August 16, 2011Assignee: DRG International, Inc.Inventors: Hasan Kulaksiz, Cyril E. Geacintov, Alfred Janetzko, Wolfgang Stremmel
-
Publication number: 20100330595Abstract: The present invention concerns methods and kits for diagnosing a disease condition characterized by non-physiological levels of hepcidin, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the mid-portion or C terminus of a hepcidin protein, and quantifying the hepcidin level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of hepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or downregulating hepcidin. The present invention further concerns therapeutic treatment of certain diseases by treatment of subjects with hepcidin and agonists or antagonists of hepcidin.Type: ApplicationFiled: May 24, 2010Publication date: December 30, 2010Applicant: DRG International Inc.Inventors: Hasan Kulaksiz, Cyril E. Geacintov, Alfred Janetzko, Wolfgang Stremmel
-
Patent number: 7749713Abstract: The present invention concerns methods and kits for diagnosing a disease condition characterized by non-physiological levels of hepcidin protein, including prohepcidin and fragments thereof, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the mid-portion or C terminus of a hepcidin protein, and quantifying the hepcidin level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of hepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or down-regulating hepcidin. The present invention further concerns therapeutic treatment of certain diseases by treatment of subjects with hepcidin and agonists or antagonists of hepcidin.Type: GrantFiled: November 19, 2003Date of Patent: July 6, 2010Inventors: Hasan Kulaksiz, Cyril E. Geacintov, Alfred Janetzko, Wolfgang Stremmel
-
Publication number: 20100086945Abstract: The present invention concerns methods and kits for diagnosing a disease condition characterized by non-physiological levels of hepcidin protein, including prohepcidin and fragments thereof, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the amino acid sequence between and including amino acids 25 and 49 of a hepcidin precursor protein, and quantifying the hepcidin precursor level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of prohepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or downregulating hepcidin.Type: ApplicationFiled: December 2, 2009Publication date: April 8, 2010Applicant: DRG International Inc.Inventors: Hasan Kulaksiz, Cyrill E. Geacintov, Alfred Janetzko, Wolfgang Stremmel
-
Patent number: 7649081Abstract: The present invention concerns methods and kits for diagnosing a disease condition characterized by non-physiological levels of hepcidin protein, including prohepcidin and fragments thereof, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the amino acid sequence between and including amino acids 25 and 49 of a hepcidin precursor protein, and quantifying the hepcidin precursor level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of prohepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or downregulating hepcidin.Type: GrantFiled: September 26, 2006Date of Patent: January 19, 2010Assignee: DRG International, Inc.Inventors: Hasan Kulaksiz, Cyril E Geacintov, Alfred Janetzko, Wolfgang Stremmel
-
Patent number: 7411048Abstract: The present invention concerns methods and kits for diagnosing a disease condition characterized by non-physiological levels of hepcidin, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the mid-portion or C terminus of a hepcidin protein, and quantifying the hepcidin level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of hepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or downregulating hepcidin. The present invention further concerns therapeutic treatment of certain diseases by treatment of subjects with hepcidin and agonists or antagonists of hepcidin.Type: GrantFiled: November 19, 2002Date of Patent: August 12, 2008Assignee: DRG International, Inc.Inventors: Hasan Kulaksiz, Cyril E. Geacintov, Alfred Janetzko, Wolfgang Stremmel
-
Patent number: 7320894Abstract: The present invention concerns methods and kits for diagnosing a disease condition characterized by non-physiological levels of hepcidin, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the mid-portion or C terminus of a hepcidin protein, and quantifying the hepcidin level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of hepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or downregulating hepcidin. The present invention further concerns therapeutic treatment of certain diseases by treatment of subjects with hepcidin and agonists or antagonists of hepcidin.Type: GrantFiled: May 19, 2003Date of Patent: January 22, 2008Assignee: DRG International, Inc.Inventors: Hasan Kulaksiz, Cyril E. Geacintov, Alfred Janetzko, Wolfgang Stremmel
-
Publication number: 20070134746Abstract: The present invention concerns methods and kits for diagnosing a disease condition characterized by non-physiological levels of hepcidin protein, including prohepcidin and fragments thereof, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the mid-portion or C terminus of a hepcidin protein, and quantifying the hepcidin level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of hepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or down-regulating hepcidin. The present invention further concerns therapeutic treatment of certain diseases by treatment of subjects with hepcidin and agonists or antagonists of hepcidin.Type: ApplicationFiled: November 19, 2003Publication date: June 14, 2007Inventors: Hasan Kulaksiz, Cyril Geacintov, Alfred Janetzko, Wolfgang Stremmel
-
Publication number: 20070092916Abstract: The present invention concerns methods and kits for diagnosing a disease condition characterized by non-physiological levels of hepcidin protein, including prohepcidin and fragments thereof, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the amino acid sequence between and including amino acids 25 and 49 of a hepcidin precursor protein, and quantifying the hepcidin precursor level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of prohepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or downregulating hepcidin.Type: ApplicationFiled: September 26, 2006Publication date: April 26, 2007Inventors: Hasan Kulaksiz, Cyril Geacintov, Alfred Janetzko, Wolfgang Stremmel